Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of CB-03-01 solution versus minoxidil and vehicle in women with androgenetic alopecia
2019-000950-78Phase 2Completed
- Sponsor
- Cassiopea S.p.A.
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clascoterone in androgenetic alopecia (AGA) (4 arms), sponsored by Cassiopea S.p.A. Primary endpoint: Co-primary efficacy endpoints. Started Apr 2019; status: completed.
02
Drugs
clascoterone
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on 2019-000950-78.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000950-78.